Reliable high-throughput functional screening with 3-FABS

Drug Discovery Today

Volumn 9, Issue 14, 2004, Pages 595-602

  Dalvit, Claudio ^a   Ardini, Elena ^b   Fogliatto, Gian Paolo ^b   Mongelli, Nicola ^a   Veronesi, Marina ^a  

^a Chemistry Department   (Italy)

^b Biology Department   (Italy)

Author keywords

19F NMR spectroscopy; Drug Discovery; false negatives; false positives; high throughput screening; IC50; KM; multiple screening; Pharmaceutical Science; Techniques Methods

Indexed keywords

DRUG;

ACCURACY; CARBON NUCLEAR MAGNETIC RESONANCE; CHEMICAL ANALYSIS; DRUG DETERMINATION; DRUG SCREENING; HIGH THROUGHPUT SCREENING; INTERMETHOD COMPARISON; MATHEMATICAL COMPUTING; MEASUREMENT; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PROTON NUCLEAR MAGNETIC RESONANCE; RELIABILITY; REVIEW;

DRUG EVALUATION, PRECLINICAL; FLUORINE RADIOISOTOPES; MAGNETIC RESONANCE SPECTROSCOPY; SUBSTRATE SPECIFICITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 3142544161     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(04)03161-7     Document Type: Review

References (61)

1. Dove A. Drug screening-beyond the bottleneck. Nat. Biotechnol. 17:1999;859-863
2. Lenz G.R., et al. Chemical ligands, genomics and drug discovery. Drug Discov. Today. 5:2000;145-156
3. Kniaz D. Drug discovery adopts factory model. Mod. Drug Discov. 3:2000;67-72
4. Smith A. Screening for drug discovery: the leading question. Nature. 418:2002;453-459
5. Cook N.D. Scintillation proximity assay: a versatile high-throughput screening technology. Drug Discov. Today. 1:1996;287-294
6. Fernandes P.B. Technological advances in high-throughput screening. Curr. Opin. Chem. Biol. 2:1998;597-603
7. Pope A.J., et al. Homogeneous fluorescence readouts for miniaturized high-throughput screening: theory and practice. Drug Discov. Today. 4:1999;350-362
8. Mere L., et al. Miniaturized FRET assays and microfluidics: key components for ultra-high-throughput screening. Drug Discov. Today. 4:1999;363-369
9. Parker G.J., et al. Development of high throughput screening assays using fluorescence polarization: nuclear receptor-ligand-binding and kinase/phosphatase assays. J. Biomol. Screen. 5:2000;77-88
10. Eggeling C., et al. Highly sensitive fluorescence detection technology currently available for HTS. Drug Discov. Today. 8:2003;632-641
11. Entzeroth M. Emerging trends in high-throughput screening. Curr. Opin. Pharmacol. 3:2003;522-529
12. Ausman D.J. Screening's age of insecurity. Mod. Drug Discov. 4:2001;33-39
13. Rishton G.M. Reactive compounds and in vitro false positives in HTS. Drug Discov. Today. 2:1997;382-384
14. Hajduk P.J., Burns D.J. Integration of NMR and high-throughput screening. Comb. Chem. High Throughput Screen. 5:2002;613-621
15. Ryan A.J., et al. Effect of detergent on "promiscuous" inhibitors. J. Med. Chem. 46:2003;3448-3451
16. McGovern S.L., et al. A specific mechanism of nonspecific inhibition. J. Med. Chem. 46:2003;4265-4272
17. Jahnke W., Widmer H. Protein NMR in biomedical research. Cell. Mol. Life Sci. 61:2004;580-599
18. Moore J.M. NMR techniques for characterization of ligand binding: utility for lead generation and optimisation in drug discovery. Biopolymers. 51:1999;221-243
19. Hajduk P.J., et al. NMR-based screening in drug discovery. Q. Rev. Biophys. 32:1999;211-240
20. Roberts G.C.K. Applications of NMR in drug discovery. Drug Discov. Today. 5:2000;230-240
21. Ross A., Senn H. Automation of measurements and data evaluation in biomolecular NMR. Drug Discov. Today. 11:2001;583-593
22. Peng J.W., et al. Nuclear magnetic resonance-based approaches for lead generation in drug discovery. Methods Enzymol. 338:2001;202-230
23. Diercks T., et al. Applications of NMR in drug discovery. Curr. Opin. Chem. Biol. 5:2001;285-291
24. Pellecchia M., et al. NMR in drug discovery. Nat. Rev. Drug Discov. 1:2002;211-219
25. Van Dongen M., et al. Structure-based screening and design in drug discovery. Drug Discov. Today. 7:2002;471-478
26. Wyss D., et al. NMR-based approaches for lead discovery. Curr. Opin. Drug Discov. Dev. 5:2002;630-647
27. Stockman B.J., Dalvit C. NMR screening techniques in drug discovery and drug design. Prog. NMR Spectrosc. 41:2002;187-231
28. Muchmore S.V., Hajduk P.J. Crystallography, NMR and virtual screening: Integrated tools for drug discovery. Curr. Opin. Drug Discov. Dev. 6:2003;544-549
29. Zartler E.R., et al. 1D NMR methods in ligand-receptor interactions. Curr. Top. Med. Chem. 3:2003;25-37
30. Fielding L. NMR methods for the determination of protein-ligand dissociation constants. Curr. Top. Med. Chem. 3:2003;39-53
31. Meyer B., Peters T. NMR spectroscopy techniques for screening and identifying ligand binding to protein receptors. Angew. Chem. Int. Ed. Engl. 42:2003;864-890
32. Coles M., et al. NMR-based screening technologies. Drug Discov. Today. 8:2003;803-810
33. Salvatella X., Giralt E. NMR-based methods and strategies for drug discovery. Chem. Soc. Rev. 32:2003;365-372
34. Hoving H., et al. Fluorine NMR studies on stereochemical aspects of reactions catalyzed by transcarboxylase, oyruvate kinase and enzyme I. Biochemistry. 24:1985;6163-6169
35. Villafranca J.J. Positional isotope exchange using Phosphorus-31 nuclear magnetic resonance. Methods Enzymol. 177:1989;390-403
36. Brindle K.M., et al. NMR methods for studying enzyme kinetics in cells and tissue. Biol. Magn. Reson. 7:1987;81-127
37. 19F NMR quantitation of lens aldose reductase activity using 3-deoxy-3-fluoro-D-glucose. J. Biol. Chem. 266:1991;20970-20975
38. 19F NMR investigations of the catalytic mechanism of phosphoglucomutase using fluorinated substrates and inhibitors. Biochemistry. 31:1992;505-512
39. Evans J.N.S. Biomolecular NMR spectroscopy. 1995;237-340 Oxford University Press
40. 13C-NMR. Chem. Pharm. Bull. (Tokyo). 46:1998;718-720
41. Segel I.H. Biochemical Calculations. 1976;John Wiley & Sons
42. Dalvit C., et al. A general NMR method for rapid, efficient and reliable biochemical screening. J. Am. Chem. Soc. 125:2003;14620-14625
43. Gerig J.T. Fluorine nuclear magnetic resonance of fluorinated ligands. Methods Enzymol. 177:1989;3-23
44. Gerig J.T. Fluorine NMR of proteins. Prog. NMR Spectrosc. 26:1994;293-370
45. Gakh Y.G., et al. Fluorine as an NMR probe for structural studies of chemical and biological systems. Magn. Reson. Chem. 38:2000;551-558
46. Panetta C.A., et al. Trifluoroacetylation of amino acids and peptides under neutral conditions. J. Org. Chem. 35:1970;4275-4277
47. Bravo P., et al. Solution and solid-phase synthesis of trfluoromethyl peptides and mimetics. J. Fluorine Chem. 112:2001;153-162
48. Jass P.A., et al. Use of N-trifluoroacetyl-protected amino acid chlorides in peptide coupling reactions with virtually complete preservation of stereochemistry. Tetrahedron. 59:2003;9019-9029
49. Coy D.H., et al. Polyfluoroalkylamine derivatives of Luteinizing hormone-releasing hormone. Biochemistry. 14:1975;1848-1851
50. Chu Y-C., et al. Possible involvement of the A20-A21 peptide bond in the expression of the biological activity of insulin. 3. [21-Desasparagine, 20-cysteine ethylamide-A]insulin and [21-desasparagine, 20-cysteine 2, 2, 2-trifluoroethylamide-A]insulin. Biochemistry. 26:1987;6975-6979
51. Langlois B., et al. Synthesis of S-trifluoromethyl-containing α-amino acids from sodium trifluoromethanesulfinate and dithio-amino acids. J. Fluorine Chem. 68:1994;63-66
52. Ojima I., et al. New potent enkephalin analogs containing trifluoromethyl-amino acid residues. Bioorg. Med. Chem. Lett. 2:1992;219-222
53. Kalbitzer H.R., et al. A new high sensitivity fluorine-19 probe for labeling cysteine groups of proteins. NMR in Biomedicine. 5:1992;347-350
54. Morris G.A., Freeman R. Enhancement of nuclear magnetic resonance signals by polarization transfer. J. Am. Chem. Soc. 101:1979;760-762
55. MacNamara E., et al. Multiplex sample NMR: an approach to high-throughput NMR using a parallel coil probe. Anal. Chim. Acta. 397:1999;9-16
56. Mestres J., Veeneman G.H. Identification of "latent hits" in compound screening collections. J. Med. Chem. 46:2003;3441-3444
57. Dalvit C., et al. Fluorine-NMR competition binding experiments for high-throughput screening of large compound mixtures. Comb. Chem. High Throughput Screen. 5:2002;605-611
58. Dalvit C., et al. Fluorine-NMR experiments for high-throughput screening: theoretical aspects, practical considerations and range of applicability. J. Am. Chem. Soc. 125:2003;7696-7703
59. Reuveni H., et al. Toward a PKB inhibitor: modification of a selective PKA inhibitor by rational design. Biochemistry. 41:2002;10304-10314
60. Obata T., et al. Peptide and protein library screening defines optimal substrate motifs for AKT/PKB. J. Biol. Chem. 275:2000;36108-36115
61. Testa J.R., Bellacosa A. AKT plays a central role in tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 98:2001;10983-10985